Results 51 to 60 of about 2,707 (196)
National Journal of Physiology, Pharmacy and Pharmacology, 2023 Background: Prostate cancer is the world's leading cause of cancer and the second cause of cancer-related death in men after lung cancer. The incidence of prostatic carcinoma is increasing with age.
Rojina Khatun +2 more
doaj +1 more source
Evaluation of immunoexpression and MDR1 promoter methylation levels in prostatic tissue samples [PDF]
, 2008 Os objectivos deste estudo foram: (1) Determinar os níveis de metilação do promotor do MDR1 em tecido prostático com adenocarcinoma (CaP), neoplasia intraepitelial prostática de alto grau (HGPIN), hiperplasia benigna (BPH) e tecido morfologicamente ...
Costa, Vera L. +5 more
core
Targeted transperineal biopsy of the prostate has limited additional benefit over background cores for larger MRI-identified tumors. [PDF]
, 2015 PURPOSE: To compare histological outcomes in patients undergoing MRI-transrectal ultrasound fusion transperineal (MTTP) prostate biopsy and determine the incremental benefit of targeted cores.
Barrett, Tristan +8 more
core +2 more sources
Molecular Carcinogenesis, Volume 64, Issue 9, Page 1487-1499, September 2025.ABSTRACT Prostate cancer (PCa) is the second leading cause of cancer‐related death among American men, and its long latency offers a window for chemopreventive strategies. Phytochemicals, with their diverse impacts on cancer cell growth and metabolism, represent promising candidates for such strategies.
Chelsea A. Friedman +5 more
wiley +1 more source
Clinics, 2008 INTRODUCTION: Sextant prostate biopsy remains the standard technique for the detection of prostate cancer. It is well known that after a diagnosis of small acinar proliferation (ASAP) or high grade prostate intraepithelial neoplasia (HGPIN), the ...
Katia Ramos Moreira Leite +5 more
doaj +1 more source
Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population. [PDF]
, 2011 BACKGROUND: Little evidence is available to determine which patients should undergo repeat biopsy after initial benign extended core biopsy (ECB). Attempts have been made to reduce the frequency of negative repeat biopsies using PSA kinetics, density ...
Doble, Andrew +4 more
core
The Prostate, Volume 85, Issue 4, Page 374-384, March 2025.ABSTRACT Background Multiparametric magnetic resonance imaging (mpMRI) is pivotal in prostate cancer (PCa) diagnosis, but some clinically significant (cs) PCa remain undetected. This study aims to understand the pathological and molecular basis for csPCa visibility at mpMRI.
Marco Oderda +12 more
wiley +1 more source
A Retrospective Study on Pathologic Features and Racial Disparities in Prostate Cancer
Prostate Cancer, 2011 We reviewed more than 3,000 pathology reports on prostate cancer-related surgical specimens and analyzed racial disparities in histological and clinical features at the time of initial biopsy, diagnosis of prostate cancer, and prostatectomy, as well as ...
Steven A. Bigler +2 more
doaj +1 more source
International Brazilian Journal of Urology, 2011 PURPOSE: To assess the diagnostic value of an initial 24-sample transrectal ultrasound guided (TRUS) prostate biopsy protocol compared to the 10-core technique.
Michael Nomikos +4 more
doaj +1 more source
CCL11 (eotaxin‐1): A new diagnostic serum marker for prostate cancer [PDF]
, 2012 BACKGROUND The recent recommendation of the U.S. Preventive Services Task Force against PSA‐based screening for prostate cancer was based, in part, on the lack of demonstrated diagnostic utility of serum PSA values in the low, but detectable range to ...
Agarwal, Manisha +4 more
core +1 more source